Brief: Algernon Pharmaceuticals Announces Completion Of Enrollment In Its Phase 2 Study Of Ifenprodil For IPF And Chronic Cough
04/02/2022 12:04
Feb 4 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS ANNOUNCES COMPLETION OF
ENROLLMENT IN
ITS PHASE 2 STUDY OF IFENPRODIL FOR IPF AND CHRONIC COUGH
Source text for Eikon: ID:nGNX48Jpg7
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement